Key result
Adding cilostazol to aspirin fails to reduce recurrent stroke risk compared to aspirin alone.
Why the study?
Stroke recurrence remains a major concern after non-cardioembolic ischemic stroke, and although dual antiplatelet therapy shows benefit in certain populations, the optimal regimen remains unclear.
Does cilostazol combined with aspirin reduce recurrent stroke in adults with acute non-cardioembolic ischemic stroke or high-risk TIA compared to aspirin alone?
Meta-Analysis (n=1,570)
Mixed
Randomized
Yes
Does cilostazol combined with aspirin reduce recurrent stroke in adults with acute non-cardioembolic ischemic stroke or high-risk TIA compared to aspirin alone?
Adding cilostazol to aspirin does not significantly reduce recurrent stroke risk compared to aspirin monotherapy in patients with non-cardioembolic stroke, though it maintains a comparable safety profile.
Answers are grounded in this paper and cite their sources.
Cilostazol plus aspirin yields no reduction in recurrent stroke versus aspirin alone; does not support routine dual therapy and leaves its niche role open.
Background Stroke recurrence remains a major concern following non-cardioembolic ischemic stroke. Dual antiplatelet therapy has shown benefit in certain populations, but the optimal regimen is unclear. Cilostazol, a phosphodiesterase-III inhibitor with antiplatelet and vasodilatory properties and a potentially lower bleeding risk, has been proposed as an alternative to clopidogrel. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy and safety of cilostazol combined with aspirin versus aspirin alone for secondary prevention after non-cardioembolic ischemic stroke. Results Four RCTs (Kwon and colleagues, 2005; Nakamura and colleagues, 2012; Uchiyama and colleagues, 2015; Aoki and colleagues, 2019) met inclusion criteria, involving 1570 participants. Pooled analysis showed no significant reduction in stroke recurrence with the aspirin–cilostazol combination (AC) compared with aspirin alone at ≤ 2 weeks (risk difference [RD]: −0.01; 95% CI −0.02 to 0.01; p = 0.48) or at 6 months (RD: −0.02; 95% CI −0.06 to 0.01; p = 0.15). There was no increase in intracerebral hemorrhage, gastrointestinal bleeding, hematuria, or serious adverse events. AC was associated with a small but significant increase in palpitations (RD: 0.02; 95% CI 0.001−0.03; p = 0.04). Numerical data on functional outcomes were not consistently reported, but qualitative assessment suggested possible benefits in neurological recovery and disability reduction. Conclusions Cilostazol plus aspirin does not significantly reduce recurrent stroke compared with aspirin monotherapy, though it maintains a comparable safety profile with only a slight increase in palpitations. This regimen may be considered for patients at high risk of hemorrhage or with clopidogrel intolerance, but current evidence does not support its routine use over standard therapy. Larger, multi-ethnic randomized trials are needed to clarify benefits in specific subgroups, such as those with intracranial stenosis, and to evaluate functional outcomes using standardized reporting. PROSPERO Registration Number: CRD42021238520.
No takes yet. Share an insight, caveat, or question.
Elshony et al. (2025) conducted a meta-analysis in Non-cardioembolic ischemic stroke or high-risk transient ischemic attack (n=1,570). Cilostazol plus aspirin vs. Aspirin monotherapy was evaluated on Stroke recurrence at 6 months (RD -0.02, 95% CI -0.06 to 0.01, p=0.15). Cilostazol plus aspirin did not reduce the risk of recurrent stroke compared with aspirin monotherapy at 6 months or 2 weeks, though it maintained a comparable safety profile.
Synapse has enriched 10 related papers. Consider them for comparative context: